Skip to content

Immunosuppressive Therapy

DRUG7 trials

Sponsors

City of Hope Medical Center, University of Nebraska, Hoffmann-La Roche, Fred Hutchinson Cancer Center, Peking Union Medical College Hospital

Conditions

Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Nasal Type Extranodal NK/T-cell LymphomaBlastic Phase Chronic Myelogenous LeukemiaChronic Graft Versus Host DiseaseChronic Myeloproliferative DisordersContiguous Stage II Adult Burkitt Lymphoma

Phase 2

Unknown Phase

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
TerminatedNCT00813501
City of Hope Medical CenterChronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection +7
Start: 2008-06-30End: 2010-06-30Updated: 2011-03-07
An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
CompletedNCT01672957
Hoffmann-La RocheKidney Transplantation
Start: 2011-09-30End: 2015-07-31Updated: 2016-10-11
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
RecruitingNCT05860400
Peking Union Medical College HospitalCoronary Artery Disease, Coronary Artery Disease Progression, Coronary Artery Restenosis +4
Start: 2023-05-17End: 2026-09-30Target: 39Updated: 2025-11-19
Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study
RecruitingNCT06845410
Peking Union Medical College HospitalCoronary Artery Disease, Coronary Artery Disease Progression, Coronary Artery Restenosis +4
Start: 2025-04-01End: 2026-12-31Target: 120Updated: 2025-11-19
Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
Not yet recruitingNCT06981845
China National Center for Cardiovascular DiseasesCoronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), In-stent Restenosis Lesion
Start: 2025-06-01End: 2028-06-01Target: 52Updated: 2025-05-21